Johnson & Johnson

10/02/2024 | Press release | Distributed by Public on 10/02/2024 07:04

ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic[...]